Table 2.
Agent | Dara/dex + additional agents (N = 7), n (%) |
---|---|
Proteasome inhibitora | 7 (100.0) |
Bortezomib | 4 (57.2) |
Carfilzomib | 3 (42.9) |
Ixazomib | 3 (42.9) |
Immunomodulatory drugs | 4 (57.1) |
Lenalidomide | 1 (25.0) |
Pomalidomide | 3 (75.0) |
Chemotherapy | 1 (14.3) |
Bendamustine | 1 (100.0) |
Cyclophosphamide | 1 (100.0) |
Dara/dex, daratumumab and dexamethasone.
Several patients received more than one proteasome inhibitor.